[A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].

Abstract

YNK01 (a daily oral dose of 450 mg) was administered for 22 days to a 58-year-old-female with Ph1-positive acute unclassified leukemia. Leukemia cells were negative for peroxidase and esterase, but were positive for CD19, CD13, CD34, CD9, HAL-DR, CD25, and TdT. Complete remission was obtained and continued for at least a month. The main side effects noted were diarrhea and melena. The administration of YNK01 resulted in plasma ara C levels that ranged between 15.4 to 23.0 ng/ml, which appear to be nearly equivalent to dose achieved during continuous IV infusion of a low dose (20 mg/m2/day) of ara C.

• Authors: M Nishikawa, K Morita, F Komada, Y Uemura, S Kageyama, N Minami, K Deguchi, S Shirakawa
• Journal: Gan no rinsho. Japan journal of cancer clinics (Gan No Rinsho) Vol. 36 Issue 12 Pg. 2204-9 (Oct 1990) ISSN: 0021-4949 [Print] Japan
• PMID: 2232191 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Arabinonucleotides
• Prodrugs
• Cytarabine
• 1-arabinofuranosylcytosine-5'-stearylphosphate
• Cytidine Monophosphate

Topics

• Acute Disease
• Administration, Oral
• Antineoplastic Agents (administration & dosage, pharmacokinetics, therapeutic use)
• Arabinonucleotides (administration & dosage, pharmacokinetics, therapeutic use)
• Cytarabine (blood)
• Cytidine Monophosphate (administration & dosage, analogs & derivatives, pharmacokinetics, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Leukemia (blood, drug therapy, metabolism)
• Middle Aged
• Prodrugs
• Remission Induction